HER2 Therapy Cardiotoxicity Index (Trastuzumab) Calculator
- HER2 Therapy Cardiotoxicity Index (Trastuzumab): Explanation and Clinical Context
Trastuzumab, a monoclonal antibody targeting the HER2 receptor, is widely used in the treatment of HER2-positive breast cancer. However, its use is associated with an increased risk of cardiotoxicity, particularly in patients with pre-existing cardiovascular conditions, older age, prior anthracycline therapy, and elevated body mass index (BMI).
The HER2 Therapy Cardiotoxicity Index is a clinical tool designed to assess the risk of cardiac dysfunction in patients undergoing trastuzumab therapy. It incorporates factors such as age, history of anthracycline use, BMI, and pre-existing cardiovascular disease to stratify patients into low, moderate, or high-risk categories.
Reference:
Sharma A, et al. "Incidence and risk factors of trastuzumab-induced cardiac dysfunction." Cardio-Oncology Journal. 2025; 10(1): 1-8. doi:10.1186/s40959-025-00319-4.
Create Note
Notes are stored privately on your device only. No login required. Nothing is uploaded or shared.
My Notes
Report this Tool
Appcardio may contain errors. Always verify the calculation and its accuracy before clinical use.